Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Johnson & Johnson 1Q Results | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Johnson & Johnson 1Q Results

Pharmaceutical sales up 10% in the quarter driven by DARZALEX, STELARA, INVEGA SUSTENNA, and IMBRUVICA.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Johnson & Johnson
1Q Revenues: $22.3 billion (+8%)
1Q Earnings: $6.2 billion (+7%)
Comments: Pharmaceutical sales were $12.2 billion in the quarter, up 10%. Sales growth in the quarter was driven by DARZALEX ($3.6 billion, +19%) for the treatment of multiple myeloma, STELARA ($2.1 billion, +18%) for the treatment of immune-mediated inflammatory diseases, ERLEADA ($261 million, +83%), a next-gen androgen receptor inhibitor for prostate cancer, TREMFYA ($418 million, +41%) for moderate to severe plaque psoriasis and active psoriatic arthritis, INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA ($965 million, +9%), a long-acting, injectable for schizophrenia, IMBRUVICA ($1.1 billion, +9%) for certain B-cell malignancies. This growth was partially offset by biosimilar and generic competition, with declines primarily in REMICADE (-22% to $777 million) and ZYTIGA (-8% to $638 million). R&D expenses were up 23% in the quarter to $3.2 billion. U.S. COVID-19 vaccine sales were $100 million in the quarter.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters